中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 968-973

Research advances in pathogenesis, risk factors, monitoring, and retreatment of drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2023.04.034

  • Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Research funding:

Chongqing Science and Health Joint Medical Research Project (2019ZDXM004)

More Information
  • Corresponding author: XIN Xiaojuan, 1152592844@qq.com (ORCID: 0000-0002-5463-9702)
  • Received Date: 2022-08-14
  • Accepted Date: 2022-09-26
  • Published Date: 2023-04-20
    Abstract
  • With the approval and launch of a large number of new drugs, the incidence rate of drug-induced liver injury (DILI) is increasing year by year, which may affect the treatment of primary diseases. As an adverse drug reaction, DILI cannot be completely eliminated, and the clinical goal is to minimize its influence through prevention and control. This article reviews the research advances in the risk factors for DILI, the monitoring of DILI, and retreatment. Studies have shown that the risk of DILI can be increased by certain factors under some circumstances. Early identification of risk factors, rational monitoring, and focus on the timing and method for retreatment can reduce the development or progression of DILI and thus improve the prognosis of patients.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    CHURCH RJ, KULLAK-UBLICK GA, AUBRECHT J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort[J]. Hepatology, 2019, 69(2): 760-773. DOI: 10.1002/hep.29802.
    [2]
    AITHAL GP, WATKINS PB, ANDRADE RJ, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011, 89(6): 806-815. DOI: 10.1038/clpt.2011.58.
    [3]
    SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. DOI: 10.1053/j.gastro.2019.02.002.
    [4]
    DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. DOI: 10.1007/s12072-021-10144-3.
    [5]
    WANG Q, HUANG A, WANG JB, et al. Chronic drug-induced liver injury: updates and future challenges[J]. Front Pharmacol, 2021, 12: 627133. DOI: 10.3389/fphar.2021.627133.
    [6]
    CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259.
    [7]
    LUCENA MI, SANABRIA J, GARCÍA-CORTES M, et al. Drug-induced liver injury in older people[J]. Lancet Gastroenterol Hepatol, 2020, 5(9): 862-874. DOI: 10.1016/S2468-1253(20)30006-6.
    [8]
    JEE A, SERNOSKIE SC, UETRECHT J. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges[J]. Int J Mol Sci, 2021, 22(6): 2954. DOI: 10.3390/ijms22062954.
    [9]
    LI X, TANG J, MAO Y. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42(9): 1999-2014. DOI: 10.1111/liv.15262.
    [10]
    KANTARJIAN H, THOMAS D, JORGENSEN J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia[J]. Cancer, 2013, 119(15): 2728-2736. DOI: 10.1002/cncr.28136.
    [11]
    GARCÍA-ROMÁN R, FRANCÉS R. Acetaminophen-induced liver damage in hepatic steatosis[J]. Clin Pharmacol Ther, 2020, 107(5): 1068-1081. DOI: 10.1002/cpt.1701.
    [12]
    SONG XA, ZHANG X, WEI ZM, et. al. The characteristics and rules of liver injury induced by antifungal drugs in elderly population[J]. World Clin Drugs, 2019, 40(12): 891-895. DOI: 10.13683/j.wph.2019.12.014.

    宋雪艾, 张昕, 魏智民, 等. 老年人群应用抗真菌药致肝损伤的特点及规律分析[J]. 世界临床药物, 2019, 40(12): 891-895. DOI: 10.13683/j.wph.2019.12.014.
    [13]
    SUN Q, ZHANG Q, GU J, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study[J]. Pharmacoepidemiol Drug Saf, 2016, 25(8): 908-917. DOI: 10.1002/pds.3988.
    [14]
    ALONSO A, MACLEHOSE RF, CHEN LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation[J]. Heart, 2017, 103(11): 834-839. DOI: 10.1136/heartjnl-2016-310586.
    [15]
    LOUVET A, NTANDJA WANDJI LC, LEMAÎTRE E, et al. Acute liver injury with therapeutic doses of acetaminophen: A prospective study[J]. Hepatology, 2021, 73(5): 1945-1955. DOI: 10.1002/hep.31678.
    [16]
    PUKENYTE E, LESCURE FX, REY D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment[J]. Int J Tuberc Lung Dis, 2007, 11(1): 78-84.
    [17]
    PARK JH, HONG S, JUN DW, et al. Prevalence and clinical characteristics of antibiotics associated drug induced liver injury[J]. Ann Transl Med, 2021, 9(8): 642. DOI: 10.21037/atm-20-5144.
    [18]
    KONG X, GUO D, LIU S, et al. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: A matched case-control study[J]. Br J Clin Pharmacol, 2021, 87(11): 4304-4312. DOI: 10.1111/bcp.14847.
    [19]
    SHAO Q, MAO X, ZHOU Z, et al. Research progress of pharmacogenomics in drug-induced liver injury[J]. Front Pharmacol, 2021, 12: 735260. DOI: 10.3389/fphar.2021.735260.
    [20]
    NICOLETTI P, AITHAL GP, BJORNSSON ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology, 2017, 152(5): 1078-1089. DOI: 10.1053/j.gastro.2016.12.016.
    [21]
    LI C, RAO T, CHEN X, et al. HLA-B*35: 01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. DOI: 10.1002/hep.30660.
    [22]
    SU Q, LIU Q, LIU J, et al. Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms[J]. Bioengineered, 2021, 12(2): 11700-11708. DOI: 10.1080/21655979.2021.2003930.
    [23]
    WATANABE I, TOMITA A, SHIMIZU M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus[J]. Clin Pharmacol Ther, 2003, 73(5): 435-455. DOI: 10.1016/s0009-9236(03)00014-6.
    [24]
    MAO L, LIN P, ZHANG W, et al. Case analysis of medical disputes related to drug-induced liver injury in Beijing from 2013 to 2019[J]. ADRJ, 2021, 23(11): 564-569. DOI: 10.3760/cma.j.cn114015-20210412-00442.

    毛璐, 林平, 张威, 等. 北京市2013—2019年药物性肝损伤相关医疗纠纷案例分析[J]. 药物不良反应杂志, 2021, 23(11): 564-569. DOI: 10.3760/cma.j.cn114015-20210412-00442.
    [25]
    Chinese Society of Tuberculosis, Chinese Medical Association. Guidelines for the management of antituberculous drug-induced liver injury (2019 edition)[J]. Chin J Tuberc Respir Dis, 2019, 42(5): 343-356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007.

    中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(5): 343-356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007.
    [26]
    MOED S, SUPRENANT M, ODJIDJA EN, et al. Economic evaluation of screening interventions for drug-induced liver injury[J]. Clin Infect Dis, 2021, 73(11): e3959-e3965. DOI: 10.1093/cid/ciaa1347.
    [27]
    MCGILL MR, STAGGS VS, SHARPE MR, et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome[J]. Hepatology, 2014, 60(4): 1336-1345. DOI: 10.1002/hep.27265.
    [28]
    DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 104-113. DOI: 10.1016/S2468-1253(17)30266-2.
    [29]
    HUNT CM, PAPAY JI, STANULOVIC V, et al. Drug rechallenge following drug-induced liver injury[J]. Hepatology, 2017, 66(2): 646-654. DOI: 10.1002/hep.29152.
    [30]
    ANDRADE RJ, ROBLES M, LUCENA MI. Rechallenge in drug-induced liver injury: the attractive hazard[J]. Expert Opin Drug Saf, 2009, 8(6): 709-714. DOI: 10.1517/14740330903397378.
    [31]
    DOUGAN M, WANG Y, RUBIO-TAPIA A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review[J]. Gastroenterology, 2021, 160(4): 1384-1393. DOI: 10.1053/j.gastro.2020.08.063.
    [32]
    HENRIKSEN JN, B∅TTGER P, HERMANSEN CK, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: Effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes[J]. Clin Genitourin Cancer, 2020, 18(1): 62-68. DOI: 10.1016/j.clgc.2019.09.013.
    [33]
    OH JH, YUN J, YANG MS, et al. Reintroduction of antituberculous drugs in patients with antituberculous drug-related drug reaction with eosinophilia and systemic symptoms[J]. J Allergy Clin Immunol Pract, 2021, 9(9): 3442-3449. DOI: 10.1016/j.jaip.2021.03.054.
    [34]
    MINERALI E, FOIL DH, ZORN KM, et al. Comparing machine learning algorithms for predicting drug-induced liver injury (DILI)[J]. Mol Pharm, 2020, 17(7): 2628-2637. DOI: 10.1021/acs.molpharmaceut.0c00326.
    [35]
    WATKINS PB. Quantitative systems toxicology approaches to understand and predict drug-induced liver injury[J]. Clin Liver Dis, 2020, 24(1): 49-60. DOI: 10.1016/j.cld.2019.09.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (413) PDF downloads(109) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return